<inglise> COUNCIL REGULATION (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin </inglise>
<eesti> N&Otilde;UKOGU M&Auml;&Auml;RUS (EM&Uuml;) nr 2377/90, milles s&auml;testatakse &uuml;henduse menetlus veterinaarravimij&auml;&auml;kide piirnormide kehtestamiseks loomsetes toiduainetes 26. juuni 1990 </eesti>
<inglise> THE COUNCIL OF THE EUROPEAN COMMUNITIES, </inglise>
<eesti> EUROOPA &Uuml;HENDUSTE N&Otilde;UKOGU, </eesti>
<inglise> Having regard to the Treaty establishing the European Economic Community, and in particular Article 43 thereof, </inglise>
<eesti> v&otilde;ttes arvesse Euroopa Majandus&uuml;henduse asutamislepingut, eriti selle artiklit 43, </eesti>
<inglise> Having regard to the proposal from the Commission (1), </inglise>
<eesti> v&otilde;ttes arvesse komisjoni ettepanekut, (1) </eesti>
<inglise> Having regard to the opinion of the European Parliament (2), </inglise>
<eesti> v&otilde;ttes arvesse Euroopa Parlamendi arvamust, (2) </eesti>
<inglise> Having regard to the opinion of the Economic and Social Committee (3), </inglise>
<eesti> v&otilde;ttes arvesse majandus- ja sotsiaalkomitee arvamust (3) </eesti>
<inglise> Whereas the use of veterinary medicinal products in food-producing animals may result in the presence of residues of foodstuffs obtained from treated animals; </inglise>
<eesti> ning arvestades, et: toiduloomadele etten&auml;htud veterinaarravimite kasutamise t&otilde;ttu v&otilde;ib ravimij&auml;&auml;ke esineda toiduainetes, mis on saadud loomadelt, kellele on manustatud ravimeid; </eesti>
<inglise> Whereas as a result of scientific and technical progress it is possible to detect the presence of residues of veterinary medicines in foodstuffs at ever lower levels; whereas it is therefore necessary to establish maximum residue limits for pharmacologically active substances which are used in veterinary medicinal products in respect of all the various foodstuffs of animal origin, including meat, fish, milk, eggs and honey; </inglise>
<eesti> teaduse ja tehnika arengu tulemusel on v&otilde;imalik tuvastada toiduainetes veterinaarravimite j&auml;&auml;ke isegi v&auml;ga madala sisalduse korral; seep&auml;rast on vaja kehtestada veterinaarravimites kasutatavate farmakoloogiliste toimeainete j&auml;&auml;kide piirnormid k&otilde;ikides loomsetes toiduainetes, kaasa arvatud liha, kala, munad ja mesi; </eesti>
<inglise> Whereas in order to protect public health, maximum residue limits must be established in accordance with generally recognized principles of safety assessment, taking into account any other scientific assessment of the safety of the substances concerned which may have been undertaken by international organizations, in particular the Codex Alimentarius or, where such substances are used for other purposes, by other scientific committees established within the Community; </inglise>
<eesti> rahva tervise kaitsmiseks tuleb j&auml;&auml;kide piirnormid kehtestada vastavalt &uuml;ldtunnustatud ohutushindamise p&otilde;him&otilde;tetele, v&otilde;ttes arvesse k&otilde;iki muid k&otilde;nealuste toimeainete teaduslikke ohutushinnanguid, mille on l&auml;bi viinud rahvusvahelised organisatsioonid, eelk&otilde;ige Codex Alimetarius, v&otilde;i muud &uuml;henduses asuvad teaduskomiteed, kui selliseid toimeaineid kasutatakse muudel eesm&auml;rkidel; </eesti>
<inglise> Whereas the use of veterinary medicinal products plays an important part in agricultural production; whereas the establishment of maximum residue levels will facilitate the marketing of foodstuffs of animal origin; </inglise>
<eesti> veterinaarravimite kasutamisel on p&otilde;llumajanduslikus tootmises oluline osa; j&auml;&auml;kide piirnormide kehtestamine h&otilde;lbustab loomsete toiduainete turustamist; </eesti>
<inglise> Whereas the establishment of different maximum residue levels by Member States may hinder the free movement of foodstuffs and of veterinary medicinal products themselves; </inglise>
<eesti> liikmesriikide kehtestatud erinevad j&auml;&auml;kide piirnormid v&otilde;ivad takistada toiduainete ja veterinaarravimite vaba liikumist; </eesti>
<inglise> Whereas it is therefore necessary to lay down a procedure for the establishment of maximum residue levels of veterinary medicinal products by the Community, following a single scientific assessment of the highest possible quality; </inglise>
<eesti> seep&auml;rast on vaja &uuml;henduse tasandil s&auml;testada veterinaarravimij&auml;&auml;kide piirnormide kehtestamise menetlus, mis p&otilde;hineks &uuml;hel v&otilde;imalikult kvaliteetsel teadushinnangul; </eesti>
<inglise> Whereas the need for the establishment of maximum residue levels throughout the Community is recognized in the Community rules relating to trade in foodstuffs of animal origin; </inglise>
<eesti> j&auml;&auml;kide piirnormide kehtestamise vajadust kogu &uuml;henduses tunnustatakse &uuml;henduse eeskirjades, mis k&auml;sitlevad loomsete toiduainetega kauplemist; </eesti>
<inglise> Whereas provisions must be adopted with a view to the systematic establishment of maximum residue levels for new substances capable of pharmacological action intended for administration to food-producing animals; </inglise>
<eesti> tuleb vastu v&otilde;tta s&auml;tted toiduloomadele manustamiseks etten&auml;htud uute farmakoloogiliste toimeainete j&auml;&auml;kide piirnormide s&uuml;stemaatiliseks kehtestamiseks; </eesti>
<inglise> Whereas arrangements must also be made for the establishment of maximum residue levels for substances which are currently used in veterinary medicines administered to food-producing animals; whereas, however, in view of the complexity of this matter and the large number of substances involved, long transitional arrangements are required; </inglise>
<eesti> samuti tuleb sisse seada kord toiduloomadele manustatavates veterinaarravimites kasutatavate toimeainete j&auml;&auml;kide piirnormide kehtestamiseks; nimetatud k&uuml;simuse keerukust ja asjaomaste toimeainete suurt hulka silmas pidades on siiski vajalik pikk &uuml;leminekuaeg; </eesti>
<inglise> Whereas, after scientific assessment by the Committee for Veterinary Medicinal Products, maximum residue levels must be adopted by a rapid procedure which ensures close cooperation between the Commission and the Member States through the Committee set up under Council Directive 81/852/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of veterinary medicinal products (4), as last amended by Directive 87/20/EEC (5); whereas an urgent procedure is also required to ensure the swift review of any tolerance which might prove insufficient to protect public health; </inglise>
<eesti> p&auml;rast veterinaarravimite komitee teadushinnangut tuleb j&auml;&auml;kide piirnormid vastu v&otilde;tta kiirmenetluse korras, mis tagab tiheda koost&ouml;&ouml; komisjoni ja liikmesriikide vahel komitee kaudu, mis loodi n&otilde;ukogu 28. septembri 1981. aasta direktiiviga 81/852/EM&Uuml; veterinaarravimite anal&uuml;&uuml;tilisi, farmakoloogilis-toksikoloogilisi ja kliinilisi standardeid ning katseprotokolle k&auml;sitlevate liikmesriikide &otilde;igusaktide &uuml;htlustamise kohta, (4) viimati muudetud direktiiviga 87/20/EM&Uuml; (5); samuti on vajalik kiirmenetlus, et tagada iga sellise h&auml;lbe kontrollimine, mis v&otilde;ib olla rahva tervise kaitseks ebapiisav; </eesti>
<inglise> Whereas medicinally induced immunological responses are usually indistinguishable from those which arise naturally, and do not affect consumers of food of animal origin; </inglise>
<eesti> ravimite kasutamisega esile kutsutud immunoloogilisi vastureaktsioone ei saa tavaliselt eristada loomulikult tekkivatest vastureaktsioonidest ning need ei m&otilde;juta loomse toidu tarbijaid; </eesti>
<inglise> Whereas the information necessary to assess the safety of residues should be presented in accordance with the principles laid down by Directive 81/852/EEC, </inglise>
<eesti> j&auml;&auml;kide ohutuse hindamiseks vajalik teave tuleks esitada vastavalt direktiivis 81/852/EM&Uuml; s&auml;testatud p&otilde;him&otilde;tetele, </eesti>
<inglise> HAS ADOPTED THIS REGULATION: </inglise>
<eesti> ON VASTU V&Otilde;TNUD K&Auml;ESOLEVA M&Auml;&Auml;RUSE. </eesti>
<inglise> Article 1 </inglise>
<eesti> Artikkel 1 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> For the purposes of this Regulation, the following definitions shall apply: </inglise>
<eesti> K&auml;esolevas m&auml;&auml;ruses kasutatakse j&auml;rgmisi m&otilde;isteid: </eesti>
<inglise> (a) 'residues of veterinary medicinal products': means all pharmacologically active substances, whether active principles, excipients or degradation products, and their metabolites which remain in foodstuffs obtained from animals to which the veterinary medicinal product in question has been administered; </inglise>
<eesti> a) veterinaarravimite j&auml;&auml;gid - k&otilde;ik farmakoloogilised toimeained (aktiivained, abiained v&otilde;i lagunemisproduktid) ja nende metaboliidid, mis s&auml;ilivad nendelt loomadelt saadud toiduainetes, kellele on manustatud veterinaarravimeid; </eesti>
<inglise> (b) 'maximum residue limit': means the maximum concentration of residue resulting from the use of a veterinary medicinal product (expressed in mg/kg or mg/kg on a fresh weight basis) which may be accepted by the Community to be legally permitted or recognized as acceptable in or on a food. </inglise>
<eesti> b) j&auml;&auml;kide piirnormid - veterinaarravimi kasutamise tulemusel tekkinud j&auml;&auml;kide maksimaalne kontsentratsioon (v&auml;ljendatuna mg/kg v&otilde;i &mgr;g/kg elusmassi kohta), mida uhendus v&otilde;ib toiduainetes v&otilde;i -ainetel aktsepteerida kui seaduslikult lubatut v&otilde;i aktsepteerituks tunnustatut. </eesti>
<inglise> It is based on the type and amount of residue considered to be without any toxicological hazard for human health as expressed by the acceptable daily intake (ADI), or on the basis of a temporary ADI that utilizes an additional safety factor. </inglise>
<eesti> J&auml;&auml;kide maksimaalne kontsentratsioon p&otilde;hineb j&auml;&auml;giliigil ja -hulgal, mida ei loeta inimese tervisele toksikoloogiliselt ohtlikuks, v&auml;ljendatuna aktsepteeritava p&auml;evadoosina (acceptable daily intake - ADI) v&otilde;i ajutise ADI alusel, mille puhul kasutatakse t&auml;iendavat ohutustegurit. </eesti>
<inglise> It also takes into account other relevant public health risks as well as food technology aspects. </inglise>
<eesti> Selle puhul v&otilde;etakse arvesse ka teisi asjakohaseid ohte rahva tervisele ning toidutehnoloogia aspekte. </eesti>
<inglise> When establishing a maximum residue limit (MRL), consideration is also given to residues that occur in food of plant origin and/or come from the environment. </inglise>
<eesti> J&auml;&auml;kide piirnormi (maximum residue limit - MRL) kehtestamisel v&otilde;etakse arvesse ka taimsetes toiduainetes leiduvaid ja/v&otilde;i keskkonnast p&auml;rinevaid j&auml;&auml;ke. </eesti>
<inglise> Furthermore, the MRL may be reduced to be consistent with good practices in the use of veterinary drugs and to the extent that practical analytical methods are available. </inglise>
<eesti> Lisaks sellele v&otilde;ib MRLi v&auml;hendada nii, et see oleks vastavuses veterinaarravimite kasutamise heade tavadega, v&otilde;i m&auml;&auml;rani, mis v&otilde;imaldab kasutada praktilisi anal&uuml;&uuml;simeetodeid. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> This Regulation shall not apply to active principles of biological origin intended to produce active or passive immunity or to diagnose a state of immunity used in immunological veterinary medicinal products. </inglise>
<eesti> K&auml;esolevat m&auml;&auml;rust ei kohaldata bioloogilist p&auml;ritolu aktiivainete suhtes, mis on ette n&auml;htud aktiivse v&otilde;i passiive immuunsuse tekitamiseks v&otilde;i immuunsusseisundi diagnoosimiseks ning mida kasutatakse immunoloogilistes veterinaarravimites. </eesti>
<inglise> Article 2 </inglise>
<eesti> Artikkel 2 </eesti>
<inglise> The list of pharmacologically active substances used in veterinary medicinal products in respect of which maximum residue limits have been established shall be contained in Annex I, which shall be adopted in accordance with the procedure laid down in Article 8. </inglise>
<eesti> Nimekiri veterinaarravimites kasutatud farmakoloogiliste toimeainete kohta, mille puhul on j&auml;&auml;kide piirnormid kehtestatud, esitatakse I lisas, mis v&otilde;etakse vastu artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Except as provided for in Article 9, any amendments to Annex I shall be adopted in accordance with the same procedure. </inglise>
<eesti> Kui artiklis 9 ei s&auml;testata teisiti, v&otilde;etakse I lisa muudatused vastu samas korras. </eesti>
<inglise> Article 3 </inglise>
<eesti> Artikkel 3 </eesti>
<inglise> Where, following an evaluation of a pharmacologically active substance used in veterinary medicinal products, it appears that it is not necessary for the protection of public health to establish a maximum residue limit, that substance shall be included in a list in Annex II, which shall be adopted in accordance with the procedure laid down in Article 8. </inglise>
<eesti> Kui veterinaarravimites kasutatud farmakoloogiliste toimeainete hindamise tulemusel selgub, et rahva tervise kaitseks ei ole vaja j&auml;&auml;kide piirnorme kehtestada, lisatakse see aine II lisas esitatud nimekirja, mis v&otilde;etakse vastu artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Except as provided for in Article 9, any amendments to Annex II shall be adopted in accordance with the same procedure. </inglise>
<eesti> Kui artiklis 9 ei s&auml;testata teisiti, v&otilde;etakse II lisa muudatused vastu samas korras. </eesti>
<inglise> Article 4 </inglise>
<eesti> Artikkel 4 </eesti>
<inglise> A provisional maximum residue limit may be established for a pharmacologically active substance used in veterinary medicinal products on the date of entry into force of this Regulation, provided that there are no grounds for supposing that residues of the substance concerned at the level proposed present a hazard for the health of the consumer. </inglise>
<eesti> Veterinaarravimites kasutatud farmakoloogiliste toimeainete puhul v&otilde;ib k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;eval kehtestada ajutise j&auml;&auml;kide piirnormi, kui ei ole alust eeldada, et asjaomase toimeaine j&auml;&auml;gid kujutaksid nende kavandataval tasemel ohtu tarbija tervisele. </eesti>
<inglise> A provisional maximum residue limit shall apply for a defined period of time, which shall not exceed five years. </inglise>
<eesti> Ajutist j&auml;&auml;kide piirnormi kohaldatakse m&auml;&auml;ratletud ajavahemikul, mis ei tohi olla pikem kui viis aastat. </eesti>
<inglise> That period may be extended once only in exceptional cases for a period not in excess of two years if that proves expedient for the completion of scientific studies in progress. </inglise>
<eesti> Seda ajavahemikku v&otilde;ib erandjuhul pikendada ainult &uuml;ks kord kuni kahe aasta ulatuses, kui see on pooleliolevate teadusuuringute l&otilde;petamiseks otstarbekas. </eesti>
<inglise> In exceptional circumstances, a provisional maximum residue limit may also be established for a pharmacologically active substance not previously used in veterinary medicinal products on the date of entry into force of this Regulation provided that there are no grounds for supposing that residues of the substance concerned at the limit proposed present a hazard for the health of the consumer. </inglise>
<eesti> Erandlikel asjaoludel v&otilde;ib ajutise j&auml;&auml;kide piirnormi kehtestada ka farmakoloogiliste toimeainete puhul, mida ei ole veterinaarravimites enne k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;eva kasutatud, kui ei ole alust eeldada, et asjaomase toimeaine j&auml;&auml;gid kujutaksid nende kavandataval tasemel ohtu tarbija tervisele. </eesti>
<inglise> The list of pharmacologically active substances used in veterinary medicinal products in respect of which provisional maximum residue limits have been established shall be contained in Annex III, which shall be adopted in accordance with the procedure laid down in Article 8. </inglise>
<eesti> Nimekiri veterinaarravimites kasutatud farmakoloogiliste toimeainete kohta, mille puhul on j&auml;&auml;kide piirnormid kehtestatud, esitatakse III lisas, mis v&otilde;etakse vastu artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Except as provided for in Article 9, any amendments to Annex III shall be adopted in accordance with the same procedure. </inglise>
<eesti> Kui artiklis 9 ei s&auml;testata teisiti, v&otilde;etakse III lisa muudatused vastu samas korras. </eesti>
<inglise> Article 5 </inglise>
<eesti> Artikkel 5 </eesti>
<inglise> Where it appears that a maximum residue limit cannot be established in respect of a pharmacologically active substance used in veterinary medicinal products because residues of the substances concerned, at whatever limit, in foodstuffs of animal origin constitute a hazard to the health of the consumer, that substance shall be included in a list in Annex IV, which shall be adopted in accordance with the procedure laid down in Article 8. </inglise>
<eesti> Kui ilmneb, et veterinaarravimites kasutatud farmakoloogilise toimeaine j&auml;&auml;kide piirnormi ei saa kindlaks m&auml;&auml;rata seet&otilde;ttu, et asjaomaste toimeainete j&auml;&auml;gid kujutavad loomsetes toiduainetes mis tahes sisalduses ohtu tarbija tervisele, lisatakse see toimeaine IV lisa nimekirja, mis v&otilde;etakse vastu artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Except as provided for in Article 9, any amendments to Annex IV shall be adopted in accordance with the same procedure. </inglise>
<eesti> Kui artiklis 9 ei s&auml;testata teisiti, v&otilde;etakse IV lisa muudatused vastu samas korras. </eesti>
<inglise> The administration of the substances listed in Annex IV to food-producing animals shall be prohibited throughout the Community. </inglise>
<eesti> IV lisas loetletud toimeainete manustamine toiduloomadele keelatakse kogu &uuml;henduses. </eesti>
<inglise> Article 6 </inglise>
<eesti> Artikkel 6 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> In order to obtain the inclusion in Annex I, II, or III of a new pharmacologically active substance which is: </inglise>
<eesti> Selleks et lisada I, II v&otilde;i III lisasse farmakoloogiline toimeaine, mis on ette n&auml;htud: </eesti>
<inglise> - intended for use in veterinary medicinal products for administration to food-producing animals, and </inglise>
<eesti> - kasutamiseks toiduloomadele manustatavates veterinaarravimites, ja </eesti>
<inglise> - intended to be placed on the market of one or more Member States which have not previously authorized the use of the substance concerned in food-producing animals, </inglise>
<eesti> - turuleviimiseks &uuml;hes v&otilde;i enamas liikmesriigis, kus k&otilde;nealuste toimeainete kasutamine toiduloomade puhul ei olnud varem lubatud, </eesti>
<inglise> the person responsible for marketing shall submit an application to the Commission. </inglise>
<eesti> esitab turustamise eest vastutav isik taotluse komisjonile. </eesti>
<inglise> The application shall contain the information and particulars referred to in Annex V and shall comply with the principles laid down in Directive 81/852/EEC. </inglise>
<eesti> Taotlus sisaldab V lisas osutatud teavet ja &uuml;ksikasju ning on vastavuses direktiivis 81/852/EM&Uuml; s&auml;testatud p&otilde;him&otilde;tetega. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> After verifying within a period of 30 days that the application is submitted in correct form, the Commission shall forthwith submit the application for examination by the Committee for Veterinary Medicinal Products set up under Article 16 of Directive 81/851/EEC. </inglise>
<eesti> P&auml;rast seda, kui 30 p&auml;eva jooksul on kontrollitud, et taotlus on esitatud &otilde;iges vormis, edastab komisjon taotluse viivitamata l&auml;bivaatamiseks direktiivi 81/851/EM&Uuml; artikliga 16 asutatud veterinaarravimite komiteele. </eesti>
<inglise> The Committee shall appoint one of its members to act as rapporteur and to undertake an initial evaluation of the application. </inglise>
<eesti> Komitee m&auml;&auml;rab &uuml;he oma liikmetest ettekandjaks, kes hakkab tegelema taotluse esialgse hindamisega. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> Within 120 days of referral of the application to the Committee for Veterinary Medicinal Products, and having regard to the observations formulated by the members of the Committee, the Commission shall prepare a draft of the measures to be taken. </inglise>
<eesti> Komisjon koostab 120 p&auml;eva jooksul p&auml;rast taotluse edastamist veterinaarravimite komiteele ja komitee liikmete m&auml;rkusi arvesse v&otilde;ttes v&otilde;etavate meetmete eeln&otilde;u. </eesti>
<inglise> If the information submitted by the person responsible for marketing is insufficient to enable such a draft to be prepared, that person will be requested to provide the Committee with additional information for examination. </inglise>
<eesti> Kui turustamise eest vastutava isiku esitatud teave ei ole sellise eeln&otilde;u koostamiseks piisav, palutakse nimetatud isikul esitada komiteele l&auml;bivaatamiseks lisateavet. </eesti>
<inglise> The rapporteur shall update the evaluation report to take account of the additional information received. </inglise>
<eesti> Ettekandja ajakohastab hindamisaruannet, et saadud lisateavet arvesse v&otilde;tta. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> Within 90 days of receipt of the additional information referred to in paragraph 3, the Commission shall prepare a draft of the measures to be taken, which shall forthwith be communicated to the Member States and the person responsible for marketing. </inglise>
<eesti> Komisjon koostab 90 p&auml;eva jooksul p&auml;rast l&otilde;ikes 3 osutatud lisateabe saamist v&otilde;etavate meetmete eeln&otilde;u, mis edastatakse viivitamata liikmesriikidele ja turustamise eest vastutavale isikule. </eesti>
<inglise> Within a further 60 days, the person responsible for marketing may, at his request, provide oral or written explanations for consideration by the Committee for Veterinary Medicinal Products. </inglise>
<eesti> Turustamise eest vastutav isik v&otilde;ib taotluse korral anda veterinaarravimite komiteele suulisi v&otilde;i kirjalikke selgitusi. </eesti>
<inglise> The Commission may, at the request of the applicant, extend this time limit. </inglise>
<eesti> Komisjon v&otilde;ib seda t&auml;htaega taotleja soovil pikendada. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> Within a further 60 days the Commission shall submit the draft measures to the Committee for the Adaptation to Technical Progress of the Directives on the Removal of Technical Barriers to Trade in the Veterinary Medicinal Products Sector, set up under Article 2b of Directive 81/852/EEC, for the application of the procedure laid down in Article 8. </inglise>
<eesti> Komisjon esitab 60 p&auml;eva jooksul meetmete eeln&otilde;u direktiivi 81/852/EM&Uuml; artikli 2b alusel asutatud veterinaarravimisektoris tehniliste t&otilde;kete k&otilde;rvaldamist k&auml;sitlevate direktiivide tehnika arengule kohandamise komiteele artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Article 7 </inglise>
<eesti> Artikkel 7 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Paragraphs 2 to 6 shall apply in respect of pharmacologically active substances which are authorized for use in veterinary medicinal products on the date of entry into force of this Regulation. </inglise>
<eesti> L&otilde;ikeid 2-6 kohaldatakse farmakoloogiliste toimeainete suhtes, mille kasutamine veterinaarravimites on k&auml;esoleva m&auml;&auml;ruse j&otilde;ustumise kuup&auml;eval lubatud. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> After consulting the Committee on Veterinary Medicinal Products, the Commission shall publish a timetable for the consideration of these substances, including time limits for submission of the information referred to in Annex V. </inglise>
<eesti> P&auml;rast veterinaarravimite komiteega konsulteerimist avaldab komisjon ajakava nende toimeainete uurimiseks, sealhulgas V lisas osutatud teabe esitamise t&auml;htajad. </eesti>
<inglise> The persons responsible for marketing the veterinary medicinal products concerned shall ensure that all relevant information is submitted to the Commission in accordance with the requirements of Annex V and in conformity with the principles laid down in Directive 81/852/EEC before expiry of the relevant time limits. </inglise>
<eesti> K&otilde;nealuste veterinaarravimite turustamise eest vastutav isik tagab, et komisjonile esitatakse kogu asjakohane teave vastavalt V lisa n&otilde;uetele ja koosk&otilde;las direktiivis 81/852/EM&Uuml; s&auml;testatud p&otilde;him&otilde;tetega enne vastava t&auml;htaja m&ouml;&ouml;dumist. </eesti>
<inglise> The competent authorities of the Member States shall bring any other relevant information to the attention of the Commission. </inglise>
<eesti> Liikmesriikide p&auml;devad asutused juhivad komisjoni t&auml;helepanu mis tahes asjakohasele teabele. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> After verifying within 30 days that the information is submitted in correct form, the Commission shall forthwith submit the information for examination to the Committee for Veterinary Medicinal Products, which shall deliver its opinion within a renewable period of 120 days. </inglise>
<eesti> P&auml;rast seda, kui 30 p&auml;eva jooksul on kontrollitud, et teave on esitatud &otilde;iges vormis, edastab komisjon teabe viivitamata l&auml;bivaatamiseks veterinaarravimite komiteele, kes esitab oma arvamuse 120p&auml;evase pikendatava ajavahemiku jooksul. </eesti>
<inglise> That Committee shall appoint one of its members to act as rapporteur and to undertake an evaluation of the information. </inglise>
<eesti> Komitee m&auml;&auml;rab &uuml;he oma liikmetest ettekandjaks, kes hakkab tegelema teabe hindamisega. </eesti>
<inglise> 4. </inglise>
<eesti> 4. </eesti>
<inglise> Having regard to the observations formulated by the members of the Committee for Veterinary Medicinal Products, the Commission shall prepare, within a maximum period of 30 days, a draft of the measures to be taken. </inglise>
<eesti> V&otilde;ttes arvesse veterinaarravimite komitee liikmete m&auml;rkusi, koostab komisjon hiljemalt 30 p&auml;eva jooksul v&otilde;etavate meetmete eeln&otilde;u. </eesti>
<inglise> If the information submitted by the person responsible for marketing is insufficient to enable such a draft to be prepared, that person will be requested to provide additional information, within a specified period, for examination by the Committee. </inglise>
<eesti> Kui turustamise eest vastutava isiku esitatud teave ei ole sellise eeln&otilde;u koostamiseks piisav, palutakse nimetatud isikul esitada kindlaksm&auml;&auml;ratud t&auml;htaja jooksul komiteele l&auml;bivaatamiseks lisateavet. </eesti>
<inglise> The rapporteur shall update the evaluation report to take account of the additional information received. </inglise>
<eesti> Ettekandja ajakohastab hindamisaruannet, et saadud lisateavet arvesse v&otilde;tta. </eesti>
<inglise> 5. </inglise>
<eesti> 5. </eesti>
<inglise> The draft of the measures to be taken shall be communicated forthwith by the Commission to the Member States and those persons responsible for marketing who have submitted information to the Commission before expiry of the time limit established in accordance with paragraph 2. </inglise>
<eesti> V&otilde;etavate meetmete eeln&otilde;u edastab komisjon viivitamata liikmesriikidele ja nendele turustamise eest vastutavatele isikutele, kes on esitanud komisjonile teabe enne l&otilde;ikes 2 s&auml;testatud t&auml;htaja m&ouml;&ouml;dumist. </eesti>
<inglise> These persons may, at their request, provide oral or written explanations to the Committee for Veterinary Medicinal Products. </inglise>
<eesti> Need isikud v&otilde;ivad omal soovil anda veterinaarravimite komiteele suulisi v&otilde;i kirjalikke selgitusi. </eesti>
<inglise> 6. </inglise>
<eesti> 6. </eesti>
<inglise> The Commission shall forthwith submit the draft measures to the Committee for Adaptation to Technical Progress of the Directives on Veterinary Medicinal Products for the application of the procedure laid down in Article 8. </inglise>
<eesti> Komisjon esitab meetmete eeln&otilde;u viivitamata veterinaarravimeid k&auml;sitlevate direktiivide tehnika arengule kohandamise komiteele artiklis 8 s&auml;testatud korras. </eesti>
<inglise> Article 8 </inglise>
<eesti> Artikkel 8 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where the procedure laid down in this Article is to be followed, the chairman shall, without delay, refer the matter to the Committee for Adaptation to Technical Progress of the Directives on Veterinary Medicinal Products either on his own initiative or at the request of a representative of a Member State. </inglise>
<eesti> Kui tuleb j&auml;rgida k&auml;esolevas artiklis s&auml;testatud menetlust, esitab eesistuja k&uuml;simuse viivitamata kas omal algatusel v&otilde;i liikmesriigi esindaja taotlusel veterinaarravimeid k&auml;sitlevate direktiivide tehnika arengule kohandamise komiteele. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The representative of the Commission shall submit a draft of the measures to be adopted to the Committee for Adaptation to Technical Progress. </inglise>
<eesti> V&otilde;etavate meetmete eeln&otilde;u esitab tehnika arengule kohandamise komiteele komisjoni esindaja. </eesti>
<inglise> The Committee shall deliver its opinion on the draft within a time limit set by the chairman, having regard to the urgency of the matter. </inglise>
<eesti> T&auml;htaja jooksul, mille m&auml;&auml;rab eesistuja l&auml;htuvalt k&uuml;simuse kiireloomulisusest, esitab komitee eeln&otilde;u kohta oma arvamuse. </eesti>
<inglise> It shall act by a qualified majority, the votes of the Member States being weighted as provided for in Article 148 (2) of the Treaty. </inglise>
<eesti> Arvamus esitatakse h&auml;&auml;lteenamusega; liikmesriikide h&auml;&auml;li arvestatakse asutamislepingu artikli 148 l&otilde;ikes 2 s&auml;testatud korras. </eesti>
<inglise> The chairman shall not vote. </inglise>
<eesti> Eesistuja ei h&auml;&auml;leta. </eesti>
<inglise> 3. (a) The Commission shall adopt the measures envisaged where they are in accordance with the opinion of the Committee. </inglise>
<eesti> 3. a) Kui kavandatavad meetmed on komitee arvamusega koosk&otilde;las, v&otilde;tab komisjon need vastu. </eesti>
<inglise> (b) Where the measures envisaged are not in accordance with the opinion of the Committee, or if no opinion is adopted, the Commission shall without delay propose to the Council the measures to be adopted. </inglise>
<eesti> b) Kui kavandatavad meetmed ei ole komitee arvamusega koosk&otilde;las v&otilde;i kui komitee ei esita oma arvamust, esitab komisjon vastuv&otilde;etavate meetmete kohta viivitamata ettepaneku n&otilde;ukogule. </eesti>
<inglise> The Council shall act by a qualified majority. </inglise>
<eesti> N&otilde;ukogu teeb otsuse kvalifitseeritud h&auml;&auml;lteenamusega. </eesti>
<inglise> (c) If, after a period of three months of the proposal being referred to it, the Council has not acted, the proposed measures shall be adopted by the Commission, unless the Council has voted against them by a simple majority. </inglise>
<eesti> c) Kui n&otilde;ukogu ei ole otsust teinud kolme kuu jooksul alates n&otilde;ukogu poole p&ouml;&ouml;rdumisest, v&otilde;tab komisjon ettepandud meetmed vastu, v&auml;lja arvatud juhul, kui n&otilde;ukogu on lihth&auml;&auml;lteenamusega olnud k&otilde;nealuste meetmete vastu. </eesti>
<inglise> Article 9 </inglise>
<eesti> Artikkel 9 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where a Member State, as a result of new information or a reassessment of existing information, considers that the urgent amendment of a provision contained in Annexes I to IV is necessary in order to protect human or animal health, and therefore requires swift action to be taken, that Member State may temporarily suspend the operation of the provision concerned in its own territory. </inglise>
<eesti> Kui p&auml;rast uue teabe saamist v&otilde;i olemasoleva teabe uut hindamist on liikmesriigi arvates vaja inimeste ja loomade tervise kaitse eesm&auml;rgil muuta kiireloomuliselt I-IV lisas esitatud s&auml;tet ning seep&auml;rast tuleks v&otilde;tta kiireid meetmeid, v&otilde;ib liikmesriik k&otilde;nealuse s&auml;tte kohaldamise oma territooriumil ajutiselt peatada. </eesti>
<inglise> In that case, it shall immediately notify the other Member States and the Commission of the measures, attaching a statement of the reasons therefor. </inglise>
<eesti> Sel juhul teatab liikmesriik viivitamata teistele liikmesriikidele ja komisjonile v&otilde;etud meetmetest ja nende p&otilde;hjustest. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The Commission shall as soon as possible examine the grounds given by the Member State concerned and, after consulting the Member States within the Committee for Veterinary Medicinal Products, it shall then deliver its opinion forthwith and take appropriate measures; the person responsible for marketing may be requested to provide the Committee with oral or written explanations. </inglise>
<eesti> Komisjon uurib niipea kui v&otilde;imalik asjaomase liikmeriigi esitatud p&otilde;hjendusi ning esitab p&auml;rast liikmesriikidega veterinaarravimite komitee raames konsulteerimist viivitamata oma arvamuse ja v&otilde;tab vajalikud meetmed; turustamise eest vastutavalt isikult v&otilde;idakse taotleda suuliste v&otilde;i kirjalike selgituste andmist komiteele. </eesti>
<inglise> The Commission shall immediately notify the Council and the Member States of any measures taken. </inglise>
<eesti> Komisjon teatab k&otilde;ikidest v&otilde;etud meetmetest viivitamata n&otilde;ukogule ja liikmesriikidele. </eesti>
<inglise> Any Member State may refer the Commission's measures to the Council within 15 days of such notification. </inglise>
<eesti> Liikmesriik v&otilde;ib komisjoni meetmed 15 p&auml;eva jooksul alates sellisest teatest n&otilde;ukogule suunata. </eesti>
<inglise> The Council, acting by a qualified majority, may take a different decision within 30 days of the date on which the matter was referred to it. </inglise>
<eesti> 30 p&auml;eva jooksul alates sellise suunamise kuup&auml;evast v&otilde;ib n&otilde;ukogu kvalifitseeritud h&auml;&auml;lteenamusega teha teistsuguse otsuse. </eesti>
<inglise> 3. </inglise>
<eesti> 3. </eesti>
<inglise> If the Commission considers that it is necessary to amend the provision of Annex I to IV concerned in order to resolve the difficulties referred to in paragraph 1 and to ensure the protection of human health, it shall initiate the procedure laid down in Article 10 with a view to adopting those amendments; the Member State which has taken measures under paragraph 1 may maintain them until the Council or the Commission has taken a decision in accordance with the abovementioned procedure. </inglise>
<eesti> Kui komisjon leiab, et l&otilde;ikes 1 nimetatud raskuste lahendamiseks ja inimeste tervise kaitse tagamiseks on vaja I- IV lisa s&auml;tet muuta, algatab ta nende muudatuste vastuv&otilde;tmiseks artiklis 10 s&auml;testatud menetluse; liikmesriik, kes on v&otilde;tnud vastu l&otilde;ikele 1 vastavad meetmed, v&otilde;ib j&auml;tkata nende kohaldamist, kuni n&otilde;ukogu v&otilde;i komisjon on eespool mainitud menetluse alusel v&otilde;tnud vastu otsuse. </eesti>
<inglise> Article 10 </inglise>
<eesti> Artikkel 10 </eesti>
<inglise> 1. </inglise>
<eesti> 1. </eesti>
<inglise> Where the procedure laid down in this Article is to be followed, the chairman shall, without delay, refer the matter to the Committee for Adaptation to Technical Progress of the Directives on Veterinary Medicinal Products either on his own initiative or at the request of a representative of a Member State. </inglise>
<eesti> Kui tuleb j&auml;rgida k&auml;esolevas artiklis s&auml;testatud menetlust, esitab eesistuja k&uuml;simuse kas omal algatusel v&otilde;i liikmesriigi esindaja taotlusel veterinaarravimeid k&auml;sitlevate direktiivide tehnika arengule kohandamise komiteele. </eesti>
<inglise> 2. </inglise>
<eesti> 2. </eesti>
<inglise> The representative of the Commission shall submit to the Committee a draft of the measures to be adopted. </inglise>
<eesti> V&otilde;etavate meetmete eeln&otilde;u esitab komiteele komisjoni esindaja. </eesti>
<inglise> The Committee shall deliver its opinion on the draft within a time limit set by the chairman, having regard to the urgency of the matter. </inglise>
<eesti> T&auml;htaja jooksul, mille m&auml;&auml;rab eesistuja l&auml;htuvalt k&uuml;simuse kiireloomulisusest, esitab komitee eeln&otilde;u kohta oma arvamuse. </eesti>
<inglise> It shall act by a qualified majority, the votes of the Member States being weighted as provided for in Article 148 (2) of the Treaty. </inglise>
<eesti> Arvamus esitatakse h&auml;&auml;lteenamusega; liikmesriikide h&auml;&auml;li arvestatakse asutamislepingu artikli 148 l&otilde;ikes 2 s&auml;testatud korras. </eesti>
<inglise> The chairman shall not vote. </inglise>
<eesti> Eesistuja ei h&auml;&auml;leta. </eesti>
<inglise> 3. (a) The Commission shall adopt the measures envisaged, where they are in accordance with the opinion of the Committee. </inglise>
<eesti> 3. a) Kui kavandatavad meetmed on komitee arvamusega koosk&otilde;las, v&otilde;tab komisjon need vastu. </eesti>
<inglise> (b) Where the measures envisaged are not in accordance with the opinion of the Committee, or if no opinion is adopted, the Commission shall without delay propose to the Council the measures to be adopted. </inglise>
<eesti> b) Kui kavandatavad meetmed ei ole komitee arvamusega koosk&otilde;las v&otilde;i kui komitee ei esita oma arvamust, esitab komisjon vastuv&otilde;etavate meetmete kohta viivitamata ettepaneku n&otilde;ukogule. </eesti>
<inglise> The Council shall act by a qualified majority. </inglise>
<eesti> N&otilde;ukogu teeb otsuse kvalifitseeritud h&auml;&auml;lteenamusega. </eesti>
<inglise> (c) If within 15 days of the proposals being submitted to it, the Council has not acted, the proposed measures shall be adopted by the Commission. </inglise>
<eesti> c) Kui n&otilde;ukogu ei ole otsust teinud 15 p&auml;eva jooksul alates ettepanekute esitamisest, v&otilde;tab komisjon ettepandud meetmed vastu. </eesti>
<inglise> Article 11 </inglise>
<eesti> Artikkel 11 </eesti>
<inglise> Any changes which are necessary to adapt Annex V to take account of scientific and technical progress shall be adopted in accordance with the procedure laid down in Article 2c of Directive 81/852/EEC. </inglise>
<eesti> Muudatused, mis on vajalikud V lisa kohandamiseks teaduse ja tehnika arenguga, v&otilde;etakse vastu direktiivi 81/852/EM&Uuml; artiklis 2c s&auml;testatud korras. </eesti>
<inglise> Article 12 </inglise>
<eesti> Artikkel 12 </eesti>
<inglise> As soon as possible after the amendment of Annexes I, II, III or IV, the Commission shall publish a summary of the assessment of the safety of the substances concerned by the Committee for Veterinary Medicinal Products. </inglise>
<eesti> Komisjon avaldab niipea kui v&otilde;imalik p&auml;rast I, II, III v&otilde;i IV lisa muutmist veterinaarravimite komitee koostatud k&otilde;nealuste toimeainete ohutushinnangu kokkuv&otilde;tte. </eesti>
<inglise> The confidential nature of any proprietary data shall be respected. </inglise>
<eesti> &Auml;risaladuse alla kuuluvad andmed on konfidentsiaalsed. </eesti>
<inglise> Article 13 </inglise>
<eesti> Artikkel 13 </eesti>
<inglise> Member States may not prohibit or impede the putting into circulation within their territories of foodstuffs of animal origin originating in other Member States on the grounds that they contain residues of veterinary medicinal products if the quantity of residue does not exceed the maximum residue limit provided for in Annex I or III, or if the substance concerned is listed in Annex II. </inglise>
<eesti> Liikmesriigid ei tohi keelata v&otilde;i takistada teistest liikmesriikidest p&auml;rinevate loomsete toiduainete ringlusse laskmist oma territooriumil p&otilde;hjusel, et need sisaldavad veterinaarravimite j&auml;&auml;ke, kui nende j&auml;&auml;kide hulk ei &uuml;leta I v&otilde;i III lisas s&auml;testatud j&auml;&auml;kide piirnormi v&otilde;i kui k&otilde;nealune toimeaine on loetletud II lisas. </eesti>
<inglise> Article 14 </inglise>
<eesti> Artikkel 14 </eesti>
<inglise> With effect from 1 January 1997, the administration to food-producing animals of veterinary medicinal products containing pharmacologically active substances which are not mentioned in Annexes I, II or III shall be prohibited within the Community, except in the case of clinical trials accepted by the competent authorities following notification or authorization in accordance with the legislation in force and which do not cause foodstuffs obtained from livestock participating in such trials to contain residues which constitute a hazard to human health. </inglise>
<eesti> Alates 1. jaanuarist 1997 keelatakse &uuml;henduses &auml;ra I, II v&otilde;i III lisas loetlemata farmakoloogilisi toimeaineid sisaldavate veterinaarravimite manustamine toiduloomadele, v&auml;lja arvatud siis, kui on tehtud kliinilised katsed, mida p&auml;devad asutused vastavalt kehtivatele &otilde;igusaktidele esitatud teatiste v&otilde;i lubade alusel lubavad ja mille tulemusel ei sisalda sellistes katsetes osalevatelt kariloomadelt saadud toiduained inimese tervisele ohtlikke j&auml;&auml;ke. </eesti>
<inglise> Article 15 </inglise>
<eesti> Artikkel 15 </eesti>
<inglise> This Regulation shall in no way prejudice the application of Community legislation prohibiting the use in livestock farming of certain substances having a hormonal action. </inglise>
<eesti> K&auml;esoleva m&auml;&auml;rus ei m&otilde;juta mingil viisil &uuml;henduse &otilde;igusaktide kohaldamist, millega keelatakse teatavate hormonaalse toimega ainete kasutamine loomakasvatuses. </eesti>
<inglise> Nothing in this Regulation shall prejudice the measures taken by Member States to prevent the unauthorized use of veterinary medicinal products. </inglise>
<eesti> K&auml;esoleva m&auml;&auml;rus ei piira liikmesriikide poolt loata veterinaarravimite kasutamise takistamiseks v&otilde;etud meetmeid. </eesti>
<inglise> Article 16 </inglise>
<eesti> Artikkel 16 </eesti>
<inglise> This Regulation shall enter into force on 1 January 1992. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus j&otilde;ustub 1. jaanuaril 1992. </eesti>
<inglise> This Regulation shall be binding in its entirety and directly applicable in all Member States. </inglise>
<eesti> K&auml;esolev m&auml;&auml;rus on tervikuna siduv ja vahetult kohaldatav k&otilde;ikides liikmesriikides. </eesti>
<inglise> Done at Luxembourg, 26 June 1990. </inglise>
<eesti> Luxembourg, 26. juuni 1990 </eesti>
<inglise> For the Council </inglise>
<eesti> N&otilde;ukogu nimel </eesti>
<inglise> The President </inglise>
<eesti> eesistuja </eesti>
<inglise> M. O'KENNEDY </inglise>
<eesti> M. O'KENNEDY </eesti>
<inglise> (1) OJ No C 61, 10.3.1989. p. 5. </inglise>
<eesti> (1) E&Uuml;T C 61, 10.03.1989, lk 5. </eesti>
<inglise> (2) OJ No C 96, 17.4.1990, p. 273. </inglise>
<eesti> (2) E&Uuml;T C 96, 17.04.1990, lk 273. </eesti>
<inglise> (3) OJ No C 201, 17.8.1989, p. 1. </inglise>
<eesti> (3) E&Uuml;T C 201, 17.08.1989, lk 1. </eesti>
<inglise> (4) OJ No L 317, 6.11.1981, p. 16. </inglise>
<eesti> (4) E&Uuml;T L 317, 6.11.1981, lk 16. </eesti>
<inglise> (5) OJ No L 15, 17.1.1987, p. 34. </inglise>
<eesti> (5) E&Uuml;T L 15, 17.01.1987, lk 34. </eesti>
 